Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

NCT03071055 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Exudative Age Related Macular Degeneration

Interventions

DRUG: Ranibizumab Injection [Lucentis]

Sponsor

Southeast Clinical Research Associates, LLC

Collaborators

[object Object]